HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.

Abstract
We have evaluated the capacity of a novel, nanoparticle-based tumor vaccine to eradicate established tumors in mice. C57BL/6 mice were intradermally (i.d.) inoculated with ovalbumin (OVA)-expressing EG-7 tumor cells. When the tumor size reached 7-8 mm, the tumor-bearing mice were i.d. injected near the tumor-draining lymph node (DLN) with liposomes encapsulated with unmethylated cytosine-phosphorothioate-guanine containing oligodeoxynucleotides (CpG-ODN) (CpG-liposomes) co-encapsulated with OVA. This vaccination protocol markedly prevented the growth of the established tumor mass and approximately 50% of tumor-bearing mice became completely cured. Tumor eradication correlated with the generation of OVA/H-2K(b)-tetramer(+) CTLs in the tumor DLN and at the tumor site with specific cytotoxicity toward EG-7 cells. Interestingly, tetramer(+) CTLs failed to be induced in lymph node-deficient Aly/Aly mice. Thus, tetramer(+) CTLs appeared to be generated in the tumor DLN and subsequently migrated into the tumor site. In vivo antibody blocking experiments revealed that CD8(+) T cells, but not CD4(+) T, NK or NKT cells, were the major effector cells mediating tumor eradication. CTL induction was also inhibited when vaccinated tumor-bearing mice were treated with both anti-IFN-alpha and anti-IFN-beta mAbs but not with anti-IFN-alpha or anti-IFN-beta mAb alone. Neither IFN-gamma(-/-) nor IL-12(-/-) mice showed impaired induction of tetramer(+) CTLs. Thus, these findings revealed that CpG-ODN-induced IFN-alpha/beta, but not IL-12 or IFN-gamma, is critical for the generation of tumor-specific CTLs in response to vaccination. These results highlight the potential utility of CpG-liposomes co-encapsulated with protein tumor antigens as therapeutic vaccines in cancer patients.
AuthorsDaiko Wakita, Kenji Chamoto, Yue Zhang, Yoshinori Narita, Daisuke Noguchi, Hideaki Ohnishi, Takeshi Iguchi, Tomoaki Sakai, Hiroaki Ikeda, Takashi Nishimura
JournalInternational immunology (Int Immunol) Vol. 18 Issue 3 Pg. 425-34 (Mar 2006) ISSN: 0953-8178 [Print] England
PMID16415100 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Adjuvants, Immunologic
  • Antigens, Neoplasm
  • CPG-oligonucleotide
  • Cancer Vaccines
  • Interferon Type I
  • Liposomes
  • Oligodeoxyribonucleotides
  • Interleukin-12
  • Interferon-gamma
  • Ovalbumin
Topics
  • Adjuvants, Immunologic (administration & dosage)
  • Animals
  • Antigens, Neoplasm (immunology)
  • Cancer Vaccines (administration & dosage, immunology, therapeutic use)
  • Female
  • Humans
  • Interferon Type I (physiology)
  • Interferon-gamma (immunology)
  • Interleukin-12 (immunology)
  • Liposomes
  • Lymph Nodes (immunology)
  • Mice
  • Mice, Inbred C57BL
  • Models, Immunological
  • Neoplasms, Experimental (prevention & control, therapy)
  • Oligodeoxyribonucleotides (administration & dosage, immunology, therapeutic use)
  • Ovalbumin (administration & dosage, immunology, therapeutic use)
  • T-Lymphocytes, Cytotoxic (immunology)
  • Th1 Cells (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: